

Gender: Female | Birth year: 1946 | WHO: 0

Tumor: Colorectum (cecum) carcinoma | Lesions: Lung, Peritoneal | Stage: IV

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Warnings
FOLFIRI	<a href="#">PHASE-3-CRC</a>  PFS: 10.0 months (95% CI: 10.0-12.0) OS: 25.0 months (95% CI: 25.0-30.0)	

Phase 2/3+ trials in NL that are open and potentially eligible (0 trials)

Trial	Cohort	Molecular	Sites	Warnings
-------	--------	-----------	-------	----------

Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">KRAS-G12D-TRIAL</a>	KRAS G12D	KRAS G12D	UMC Utrecht	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Molecular Details

NGS & MSI Panel (15-Jan-2023)

Biopsy location	Lung
Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

IHC results


Ki67	Positive, score 90%
PD-L1	Score < 50%

Efficacy evidence


Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.


Treatment	Literature efficacy evidence												
FOLFIRI	<div><a href="#">PHASE-3-CRC</a> <b>Patient characteristics:</b><table><tr><td>WHO/ECOG</td><td>0: 100, 1: 80, 2: 20, 3: 0, 4: 0</td></tr><tr><td>Primary tumor location</td><td>Left: 145, Both or unknown: 10, Right: 45</td></tr><tr><td>Mutations</td><td>KRAS exon 2 wild-type 200/200</td></tr><tr><td>Metastatic sites</td><td>Liver only: 58 (32.0%), Lung only: 10 (6.0%)</td></tr><tr><td>Previous systemic therapy</td><td>35/200</td></tr><tr><td>Prior therapies</td><td>Adjuvant chemotherapy</td></tr></table> <b>Median PFS:</b> 10.0 months (95% CI: 10.0-12.0) <b>Median OS:</b> 25.0 months (95% CI: 25.0-30.0)</div>	WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0	Primary tumor location	Left: 145, Both or unknown: 10, Right: 45	Mutations	KRAS exon 2 wild-type 200/200	Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)	Previous systemic therapy	35/200	Prior therapies	Adjuvant chemotherapy
WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0												
Primary tumor location	Left: 145, Both or unknown: 10, Right: 45												
Mutations	KRAS exon 2 wild-type 200/200												
Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)												
Previous systemic therapy	35/200												
Prior therapies	Adjuvant chemotherapy												




y



y





Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

Clinical Details

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	None
Known allergies	Morphine
Recent surgeries	12-Nov-2021 Hemicolectomy right

Tumor details (05-Mar-2023)

Measurable disease	Yes
Known lesions	Lung, Peritoneal
Unknown lesions	Lymph node
No lesions present	CNS, Brain, Liver, Bone

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023



Trial Matching Details

Trials and cohorts that are potentially eligible, but are closed (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
METC 01 IEMOEN	Applies to all cohorts below	None		Has not exhausted SOC
	Dose escalation - monotherapy			
	Dose expansion - monotherapy			

Trials and cohorts that are considered ineligible (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02</a> <a href="#">KAYRAS</a>	Applies to all cohorts below	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0 trials)

Trial	Cohort	Molecular	Sites	Configuration
None				